HalioDx reports progress on clinical research services

HalioDx SAS has released a report detailing the progress being made by its clinical research services.
The report outlines how HalioDx is incorporating its proprietary technologies into its clinical trials for groundbreaking drugs falling under the category of immune-modulatory to further its ambition in becoming a preferred partner of biopharmaceutical companies when it comes to the developing precision immunotherapy.
"The significant success of our clinical research offer to biopharmaceutical partners, thanks to the scientific contribution of our co-founder Dr. [Jerome] Galon combined with our experienced team and capabilities, attract more and more Biopharma partners" HalioDX co-founder and Chief Executive Officer Vincent Fert said. "These assets and our unique offering of proprietary immune oncology assays, ready to be embarked on companion diagnostic projects, represent a strong competitive advantage. We are now looking forward to the first results to be presented by our biopharmaceutical partners at ASCO 2017."
This year, HalioDx has finalized seven master service agreements with biopharmaceutical companies located in the United States and in Europe. These agreements allow HalioDx to provide a full range of proprietary tests within its clinical research, including Phase I through Phase III trials.